Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs

4Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

The developmental speed of new antimicrobials does not meet the emergence of multidrugresistant bacteria sufficiently. A potential shortcut is assessing the antimicrobial activity of already approved drugs. Intrudingly, the antibacterial action of glatiramer acetate (GA) has recently been discovered. GA is a well-known and safe immunomodulatory drug particular effective against Gram-negative bacteria, which disrupts biological membranes by resembling the activity of antimicrobial peptides. Thus, GA can potentially be included in treatment strategies used to combat infections caused by multidrug-resistant Gram-negatives. One potential application is chronic respiratory infections caused by Pseudomonas aeruginosa, however the safety of GA inhalation has never been assessed. Here, the safety of inhaling nebulized GA is evaluated in a preclinical pig model. The potential side effects, i.e., bronchoconstriction, respiratory tract symptoms and systemic- and local inflammation were assessed by ventilator monitoring, clinical observation, biochemistry, flowcytometry, and histopathology. No signs of bronchoconstriction assessed by increased airway peak pressure, Ppeak, or decreased oxygen pressure were observed. Also, there were no signs of local inflammation in the final histopathology examination of the pulmonary tissue. As we did not observe any potential pulmonary side effects of inhaled GA, our preliminary results suggest that GA inhalation is safe and potentially can be a part of the treatment strategy targeting chronic lung infections caused by multidrug-resistant Gram-negative bacteria.

References Powered by Scopus

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

2285Citations
N/AReaders
Get full text

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial

1842Citations
N/AReaders
Get full text

New uses for old drugs

869Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Multiple roles of ribosomal antimicrobial peptides in tackling global antimicrobial resistance

17Citations
N/AReaders
Get full text

Culprit or correlate? An application of the Bradford Hill criteria to Vitamin E acetate

10Citations
N/AReaders
Get full text

Compiling Evidence for EVALI: A Scoping Review of In Vivo Pulmonary Effects After Inhaling Vitamin E or Vitamin E Acetate

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Skovdal, S. M., Christiansen, S. H., Johansen, K. S., Viborg, O., Bruun, N. H., Jensen-Fangel, S., … Petersen, E. (2019). Inhaled nebulized glatiramer acetate against Gram-negative bacteria is not associated with adverse pulmonary reactions in healthy, young adult female pigs. PLoS ONE, 14(10). https://doi.org/10.1371/journal.pone.0223647

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

65%

Researcher 4

24%

Professor / Associate Prof. 2

12%

Readers' Discipline

Tooltip

Immunology and Microbiology 5

38%

Agricultural and Biological Sciences 3

23%

Medicine and Dentistry 3

23%

Pharmacology, Toxicology and Pharmaceut... 2

15%

Save time finding and organizing research with Mendeley

Sign up for free